STAT3 inhibitor formulation

US10913709B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• GLG Pharma, LLC · US
• MRIGlobal · US

Inventors

• Robert H. Shoemaker · Royal Oak, US
• Michael W. Lovell · Syracuse, US
• Jonathan White · Melbourne, AU
• Shanker Gupta · Bethesda, US

Key dates

• Filing date: Apr 5, 2018
• Grant date: Feb 9, 2021
• Expiry date: Apr 5, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a salt prepared from the STAT3 inhibitor known as 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino] benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol. The salt is soluble in water and stable for extended periods of time. Further provided are pharmaceutical compositions comprising the salt and methods of administering the salt to prevent and treat cancer, such as breast cancer.